Turnaturi Rita, Arico Giuseppina, Ronsisvalle Giuseppe, Pasquinucci Lorella, Parenti Carmela
Department of Drug Sciences-Medicinal Chemistry Section, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
Curr Med Chem. 2016;23(40):4506-4528. doi: 10.2174/0929867323666161024151734.
Polypharmacology, or the associations between two or more drugs producing biological effects on two or more different sites of action could represent a possible therapeutic approach for the clinical management of acute and chronic pain. The multitude and complexity of neuronal mechanisms that contribute to pain transmission provide several possible targets for pharmacological intervention. Thus, multitarget ligands possessing opioid-opioid or non-opioid-opioid mechanisms of action are potential drug candidates for pain relief. In this perspective, the past medicinal chemistry paradigm "one-target, one-disease" has been reconsidered and converted into "one-molecule, multiple targets". Multitarget ligands in comparison with cocktail drugs, besides an improved analgesic effect, display a more predictable pharmacokinetic and pharmacodynamic profile coupled to a less incidence of side-effects. Thus, they ameliorate patient compliance and decrease the risk of drug-drug interactions. In our previous review multitarget ligands with an opioid-opioid mechanism of action were described. Here, we deal with multitarget ligands with opioid-non opioid mechanism of action as potential drug candidates for the management of different pain states.
多药理学,即两种或更多种药物在两个或更多个不同作用位点产生生物学效应之间的关联,可能代表了一种用于急性和慢性疼痛临床管理的潜在治疗方法。导致疼痛传递的神经元机制的多样性和复杂性为药理学干预提供了几个可能的靶点。因此,具有阿片-阿片或非阿片-阿片作用机制的多靶点配体是缓解疼痛的潜在候选药物。从这个角度来看,过去的药物化学范式“一个靶点,一种疾病”已经被重新审视并转变为“一个分子,多个靶点”。与复方药物相比,多靶点配体除了具有改善的镇痛效果外,还显示出更可预测的药代动力学和药效学特征,同时副作用发生率更低。因此,它们改善了患者的依从性并降低了药物相互作用的风险。在我们之前的综述中,描述了具有阿片-阿片作用机制的多靶点配体。在这里,我们探讨具有阿片-非阿片作用机制的多靶点配体作为管理不同疼痛状态的潜在候选药物。